

The Six-Minute Step Test as a Predictor of Functional Capacity according to Peak $\text{VO}_{2\text{peak}}$ in Cardiac Patients

Luiz Eduardo Fonteles Ritt,^{1,2} Eduardo Sahade Darzé,^{1,2} Gustavo Freitas Feitosa,¹ Jessica Santana Porto,¹ Gabriela Bastos,¹ Renata Braga Linhares de Albuquerque,² Cristiane Miura Feitosa,¹ Thaissa Costa Claro,¹ Eloisa Ferreira Prado,¹ Queila Borges de Oliveira,¹ Ricardo Stein^{3,4}

Hospital Córdio Pulmonar,¹ Salvador, BA - Brazil

Escola Bahiana de Medicina e Saúde Pública,² Salvador, BA - Brazil

Hospital de Clínicas de Porto Alegre,³ Porto Alegre, RS - Brazil

Universidade Federal do Rio Grande do Sul,⁴ Porto Alegre, RS - Brazil

Abstract

Background: Six-minute step test (6MST) is a simple way to evaluate functional capacity, although it has not been well studied in patients with coronary artery disease (CAD) or heart failure (HF).

Objective: Analyze the association between the 6MST and peak oxygen uptake ($\text{VO}_{2\text{peak}}$) and develop an equation for estimating $\text{VO}_{2\text{peak}}$ based on the 6MST, as well as to determine a cutoff point for the 6MST that predicts a $\text{VO}_{2\text{peak}} \geq 20 \text{ mL.Kg}^{-1}.\text{min}^{-1}$

Methods: In 171 patients who underwent the 6MST and a cardiopulmonary exercise test, correlation, regression, and ROC analysis were used and a $p < 0.05$ was admitted as significant.

Results: mean age was 60 ± 14 years and 74% were male. Mean left ventricle ejection fraction was $57 \pm 16\%$, 74% had CAD and 28% had HF. Mean $\text{VO}_{2\text{peak}}$ was $19 \pm 6 \text{ mL.Kg}^{-1}.\text{min}^{-1}$ and mean 6MST performance was 87 ± 45 steps. Association between 6MST and $\text{VO}_{2\text{peak}}$ was $r 0.69$ ($p < 0.001$). The model $\text{VO}_{2\text{peak}} = 19.6 + (0.075 \times 6\text{MST}) - (0.10 \times \text{age})$ for men and $\text{VO}_{2\text{peak}} = 19.6 + (0.075 \times 6\text{MST}) - (0.10 \times \text{age}) - 2$ for women could predict $\text{VO}_{2\text{peak}}$ based on 6MST results (adjusted R 0.72 ; adjusted $R^2 0.53$). The most accurate cutoff point for 6MST to predict a $\text{VO}_{2\text{peak}} \geq 20 \text{ mL.Kg}^{-1}.\text{min}^{-1}$ was > 105 steps (AUC 0.85 ; 95% CI $0.79 - 0.90$; $p < 0.001$).

Conclusion: An equation for predicting $\text{VO}_{2\text{peak}}$ based on 6MST results was derived, and a significant association was found between 6MST and $\text{VO}_{2\text{peak}}$. The cutoff point for 6MST, which predicts a $\text{VO}_{2\text{peak}} \geq 20 \text{ mL.Kg}^{-1}.\text{min}^{-1}$, was > 105 steps. (Arq Bras Cardiol. 2021; 116(5):889-895)

Keywords: Heart Failure; Oxygen Consumption; Respiratory Capacity; Tidal Volume; Exercise Test.

Introduction

In cardiovascular disease, functional capacity is directly related to prognosis.¹ Functional performance, as determined by peak oxygen consumption ($\text{VO}_{2\text{peak}}$) and measured with a cardiopulmonary exercise test (CPET), is the gold standard and is used to determine prognosis in heart failure (HF) and heart transplant selection, as well as to gauge therapeutic response.²⁻⁴ Patients with a $\text{VO}_{2\text{peak}}$ below $15 \text{ mL.Kg}^{-1}.\text{min}^{-1}$ have a worse prognosis profile, and those with a $\text{VO}_{2\text{peak}}$ above $20 \text{ mL.Kg}^{-1}.\text{min}^{-1}$ have a better prognosis profile, independent of HF etiology and ventricular function.^{5,6} Although widely used and validated, the CPET is not available in most centers, since the equipment is expensive and a specialized physician is required to administer the test and interpret its results.

One alternative to CPET is the six-minute walk test (6MWT), which is well validated and has a good correlation with CPET in cardiomyopathy patients.⁷ However, the 6MWT requires a long corridor (at least 30 meters), which could limit its use in normal practice.

The six-minute step test (6MST) is a simple test in which the patient climbs and descends a 2-step ladder for 6 minutes in free cadence, and the number of steps the patient takes is counted. It requires neither sophisticated equipment nor large spaces. Although studied in patients with chronic lung disease and in normal subjects,⁸⁻¹¹ there are no data on 6MST performance in cardiac patients.

The objectives of this study were to: (1) analyze the association between 6MST and $\text{VO}_{2\text{peak}}$, (2) develop an equation for estimating $\text{VO}_{2\text{peak}}$ based on 6MST results, and (3) determine a cutoff point for lower risk category in the 6MST ($\text{VO}_{2\text{peak}} \geq 20 \text{ mL.Kg}^{-1}.\text{min}^{-1}$).

Methods

In this cross-sectional study, we evaluated patients referred for cardiac rehabilitation between May 2014 and

Mailing Address: Luiz Eduardo Fonteles Ritt •

Centro de Estudos Clínicos - Hospital Córdio Pulmonar - Avenida Anita Garibaldi, 2199. Postal Code 40170-130, Ondina, Salvador, BA - Brazil

E-mail: luizritt@hotmail.com, lefr@cardiol.br

Manuscript received September 11, 2019, revised manuscript March 16, 2020, accepted April 08, 2020

DOI: <https://doi.org/10.36660/abc.20190624>

September 2017 who, as per clinical protocol, underwent symptom-limited CPET and 6MST as their baseline evaluation in the cardiac rehabilitation program of the Hospital Córdio Pulmonar, Salvador, Brazil.

The inclusion criteria were patients older than 18 years who had been diagnosed with coronary artery disease (CAD) or heart failure (HF), characterized by previous acute myocardial infarction, coronary angioplasty/stent placed post-operatively to cardiac or vascular surgery, or patients with implantable devices such as pacemakers or cardiac defibrillators. These individuals were referred to the cardiac rehabilitation program and underwent an initial evaluation with a cardiologist and a physical therapist. CAD and/or HF diagnosis was established by medical history (acute myocardial infarction, stable CAD, myocardial revascularization or angioplasty, or symptoms of dyspnea or angina), electrocardiographic abnormalities (pathological Q waves) and echocardiographic abnormalities (ventricular dysfunction and segmental abnormalities).

The exclusion criteria were inability to perform the CPET or the 6MST. Patients with symptoms of angina or ischemia at an stage lower than the anaerobic threshold were also excluded as they were not submitted to the 6MST.

Clinical and demographic data were retrieved from the initial cardiologist evaluation on the day of the CPET, including the most recent (within the last 3 months) echocardiogram. The CPET and 6MST were applied separately, 2 to 7 days apart.

The 6MST was performed on a 20 cm high step covered with non-slip rubber. Patients were instructed to go up and down the step as fast as possible for 6 minutes without using their arms to support themselves; rest breaks were permitted.

A symptom-limited CPET was performed on a treadmill with a gas analyzer (Cortex, Leipzig, Germany) with breath-by-breath measurements. An individualized ramp protocol based on the functional class of each patient was used, having a targeted exercise phase duration between 8 and 12 minutes. The collected ventilatory data were tabulated and analyzed at 10-second intervals.

Ethical aspects: the study protocol was approved by the Celso Figueiroa Research Ethics Committee of the Hospital Santa Izabel (case 1.711.505). The study was conducted in accordance with national and international legislation for human research, including the Helsinki guidelines and resolution 466/12 of the Brazilian National Health Council. Informed consent was exempted since the study utilized only medical record data.

Statistical Analysis

SPSS version 25.0 was used for all analyses. Continuous variables were presented as mean ± standard deviation (SD) for parametric distribution. The Shapiro-Wilk test and visual inspection of histograms were used to determine normality. Categorical variables were presented as proportion or percentage. The Pearson correlation was applied to determine associations between continuous variables and Bland-Altman plots to analyze their agreement. Univariate and multivariate linear regression analyses (after adequate assumptions were analyzed) were performed to determine the model's prediction of VO_{2peak} based on the 6MST, which was controlled for age, ejection fraction, sex, presence of CAD or HF, and

weight. ROC curve analysis was applied to determine the best cutoff points for predicting a $VO_{2peak} \geq 20 \text{ mL}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$. A p-value <0.05 was considered significant for all analyses.

Results

The total sample consisted of 171 patients. Table 1 shows their general demographic and clinical characteristics. Most patients were in NYHA class I or II (54% and 24%, respectively) with a mean VO_{2peak} of $19 \pm 6 \text{ mL}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$.

Figure 1 shows the association between 6MST and VO_{2peak} ; the r correlation index was 0.69 (95% CI 0.60 – 0.78; $p < 0.001$) and the R^2 was 0.47. Figure 2 shows the Bland-Altman plot analysis, and in only 5 patients the agreement was away from the upper or the lower reference limit.

In the multivariate analysis, age, sex and 6MST result were independent predictors of VO_{2peak} (Table 2). The equations for estimating VO_{2peak} based on 6MST were: $VO_{2peak} = 19.6 + (0.075 \times 6MST) - (0.10 \times \text{age})$ for men, and $VO_{2peak} = 19.6 + (0.075 \times 6MST) - (0.10 \times \text{age}) - 2$ for women. The final model's adjusted r was 0.72 and the adjusted R^2 was 0.53.

Figure 3 shows the ROC curve for the 6MST as a predictor of $VO_{2peak} \geq 20 \text{ mL}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$. The most accurate cutoff point for 6MST prediction of $VO_{2peak} \geq 20 \text{ mL}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ was >105 steps (AUC 0.85, 95% CI 0.79-0.90, $p < 0.001$).

Table 1 – General demographic and clinical characteristics of the population

Variable	Result
Male % (n)	74% (121)
Age (years)	60±14
CAD % (n)	74% (121)
Heart failure %(n)	28% (47)
Cardiac valvular disease %(n)	13% (22)
Diabetes %(n)	25% (44)
Hypertension %(n)	62% (102)
NYHA I, II, III%	53%/24%/10%
ACE inhibitor-ARB %(n)	65% (110)
Beta-blocker %(n)	77% (130)
Statins %(n)	75% (128)
Ejection fraction (%)	57±16
VO_{2peak} ($\text{mL}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$)	19±6
VO_2 at anaerobic threshold ($\text{mL}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$)	12.6±3
RER	1.12±0.8
VE/ VO_2 slope	36±10
6MST (steps)	85±47

CAD: coronary artery disease; NYHA: New York Heart Association; ACE: angiotensin receptor enzyme; ARB: angiotensin receptor blocker; RER: respiratory exchange ratio.




Figure 1 – Association between 6MST and VO_{2peak}




Figure 2 – Bland-Altman plot for predicted versus determined VO_{2peak}

Table 2 – Final multiple linear regression model for predicting VO_{2peak} based on the 6MST

Variable	Beta	Beta 95% CI	p
6MST	0.075	(0.06) – (0.09)	<0.001
Age (years)	-0.10	(-0.16) – (-0.5)	<0.001
Female	-2.0	(-3.6) – (-0.33)	0.02
Constant	19.6	(15.2) – (24.1)	<0.001

Adjusted for age, ejection fraction, coronary artery disease, heart failure, and weight. 6MST: six-minute step test; OR: odds ratio; CI: confidence interval.




Figure 3 – ROC curve for 6MST to predict a $VO_{2peak} \geq 20 \text{ mL.Kg}^{-1}.\text{min}^{-1}$ AUC 0.85 (95% CI 0.79 – 0.90) $p < 0.001$.

Discussion

Functional capacity is one of the most important clinical parameters for measuring functional capacity.¹ Functional impairment is related to worse prognosis, independently of the diagnosis or clinical scenario.^{1,7} Cardiorespiratory fitness (CRF) can be estimated by several methods, although the CPET is the only method that allows direct determination based on VO_{2peak} . Since the CPET requires specific equipment and well-trained medical staff, an accurate indirect measurement of functional capacity is highly desirable. Simpler alternative forms of CRF evaluation are important to be validated as they may be more broadly applied.

In a population of CAD and HF patients, we demonstrated that the 6MST had a good correlation with VO_{2peak} as measured by CPET. We were also able to derive an equation to predict VO_{2peak} based on 6MST results, as well as to determine a cutoff point for the number of steps necessary to identify lower-risk patients (minimum VO_{2peak} of $20 \text{ mL.Kg}^{-1}.\text{min}^{-1}$).

Step Test in Cardiology

Step tests are not a new tool in cardiology. Back in the 1930s, Master et al.⁸ used a 1-step stair test in a 2-minute protocol to observe exercise ECGs. This was the precursor of actual exercise stress tests using ergometers. The Master step test was widely used as a provocative test for coronary ischemia, but was not routinely used for predicting CRF/functional capacity and prognosis. The main purpose of the 6MST as a submaximal test is to determine CRF and not to diagnose coronary ischemia. As well as the 6MWT, the 6MST is safe and can be performed at submaximal effort, although with a slightly higher energy expenditure.

Functional Capacity as a Vital Sign

Functional capacity can be considered a vital sign and should be assessed in each clinical visit.^{9,10} It can be predicted with a regular exercise test or submaximal functional tests such as the 6MWT, but the CPET is the only way to directly assess and determine functional capacity. Based on classic studies of cardiac patients, a VO_{2peak} above $20 \text{ mL.kg}^{-1}.\text{min}^{-1}$

is a marker of good prognosis regardless of other parameters, whereas those with a VO_{2peak} below $12 \text{ mL}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ and HF may even be considered candidates for heart transplant.^{5,6}

As an alternative to CPET, the 6MWT has been validated and is used for prognostic evaluation in different diseases.¹¹ It is easy to replicate and can be related to outcome, but the requirement of a large space prevents its use in office settings. Therefore, a test that can estimate functional capacity in the office without the need for sophisticated equipment is of value.

It is important to point out that the 6MST was previously compared to the 6MWT in a population free of cardiac or pulmonary diseases and showed good correlation.¹²

The 6-minute Step Test is a Simple Way to Predict Functional Capacity

The 6MST is a simple test that does not require much space. It can be applied in a medical office or by other health professionals. It has been previously used in patients with chronic pulmonary disease, but it has not yet been validated in cardiac patients.

In patients with chronic obstructive pulmonary disease, a cutoff point of <78 steps was associated with worse prognosis.¹³ In a healthy population with a mean age of 39 years, the mean step count was 149 ± 34 .¹⁴

According to our data, the 6MST has acceptable accuracy for predicting VO_{2peak} in a sample of CAD/HF patients, and clinicians may want to use these results in their clinical practice.

We found that the cutoff point of >105 steps is related to achieving a VO_{2peak} above $20 \text{ mL}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$. This cutoff may be useful, for example, when CPET is not available. Furthermore, if a patient can climb more than 105 steps, a CPET may not be necessary, since a VO_{2peak} above $20 \text{ mL}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ is estimated.

Functional capacity estimates based on daily life activities are inaccurate and have not been directly validated through CPET data,¹⁵ although this strategy is still used when prompt estimates are necessary, even for serial evaluation. Thus, the 6MST can be easily and quickly applied, but with more confidence regarding the determination of functional capacity.

Limitations

This study has some limitations. A larger sample size and prospective validation of these results in other populations should be considered. Our population consisted of CAD and/or HF patients who were analyzed together, and one may want to analyze these phenotypes separately. To mitigate the influence of the clinical diagnosis on the performance of the test, we controlled the multivariate analysis for the diagnosis of HF or CAD and found that the diagnosis did not influence the result. Also, we controlled the analysis for ejection fraction. As CAD is the most prevalent cause of HF and functional capacity is an independent prognostic factor for both, having a test and a single cutoff point that can be applied to a broader spectrum of heart disease may be of value as the 6MST may be better applied to triage and follow-up. The Bland-Altman plot analysis showed that in only 5 patients the agreement was considered away from the upper or lower reference limits. Of these, 4 patients had VO_{2peak} above $20 \text{ mL}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ and the predicted value

from the 6MST was also greater than $20 \text{ mL}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$. Thus, these 4 patients would not be misclassified as having a lower risk than expected. In 1 patient, the VO_{2peak} predicted by the 6MST was higher than the measured one. By analyzing this case, we note that the CPET respiratory exchange ratio was just 0.94 compatible with a submaximal effort, which was due to poor adaptation to the treadmill and mask. This same patient climbed up and down 91 steps in 6 minutes. One may understand that the 6MST is more suitable as a triage tool than as a substitute for the CPET. Therefore, although they are correlated, in cases in which functional capacity needs to be exactly determined, the CPET is still needed. At the present moment, we have no 6MWT performance data for these individuals, although a correlation between the tests in these patients could be of value. Studies correlating the performance of the 6MST in terms of clinical outcomes should provide more information about the best cutoff points. Finally, although CPET VO_{2peak} is the gold standard for functional evaluation, it is possible that the 6MST could provide some prognostic implications according to the results.

Conclusion

An equation capable of predicting VO_{2peak} based on 6MST results was derived, and a significant association was found between 6MST and VO_{2peak} . The cutoff point for the 6MST, which predicts a $VO_{2peak} \geq 20 \text{ mL}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$, was >105 steps.

Acknowledgements

Partial financial support was provided by the FIPE-HCPA (Research Support Fund of the Hospital de Clínicas de Porto Alegre).

Author Contributions

Conception and design of the research: Ritt LE, Porto JS, Bastos G, Feitosa CM, Claro TC, Prado EF, Oliveira QB, Stein R; Acquisition of data: Ritt LE, Feitosa GF, Porto JS, Bastos G, Albuquerque RBL, Feitosa CM, Claro TC, Prado EF, Oliveira QB, Stein R; Analysis and interpretation of the data: Ritt LE, Darzé ES, Feitosa GF, Porto JS, Bastos G, Prado EF, Stein R; Statistical analysis: Ritt LE, Darzé ES, Porto JS, Bastos G, Albuquerque RBL, Oliveira QB, Stein R; Obtaining financing: Ritt LE, Stein R; Writing of the manuscript: Ritt LE, Darzé ES, Feitosa GF, Porto JS, Bastos G, Albuquerque RBL, Oliveira QB, Stein R; Critical revision of the manuscript for intellectual content: Ritt LE, Darzé ES, Feitosa GF, Porto JS, Bastos G, Feitosa CM, Claro TC, Prado EF, Stein R.

Potential Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Sources of Funding

There were no external funding sources for this study.

Study Association

This study is not associated with any thesis or dissertation work.

References

1. Forman DE, Arena R, Boxer R, Dolansky MA, Eng JJ, Fleg JL, et al. Prioritizing Functional Capacity as a Principal End Point for Therapies Oriented to Older Adults with Cardiovascular Disease: A Scientific Statement for Healthcare Professionals from the American Heart Association. *Circulation*. 2017;135(16):e894–918.
2. Task Force of the Italian Working Group on Cardiac Rehabilitation and Prevention. Statement on cardiopulmonary exercise testing in chronic heart failure due to left ventricular dysfunction: recommendations for performance and interpretation Part III: Interpretation of cardiopulmonary exercise testing in chronic heart failure and future. *Eur J Cardiovasc Prev Rehabil*. 2006;13(4):485–94.
3. Fletcher GF, Ades PA, Kligfield P, Arena R, Balady CJ, Bittner VA, et al. Exercise standards for testing and training: A scientific statement from the American heart association. *Circulation*. 2013;128(8):873–934.
4. Malhotra R, Bakken K, D'Elia E, Lewis GD. Cardiopulmonary Exercise Testing in Heart Failure. *JACC Hear Fail*. 2016;4(8):607–16.
5. Myers J, Gullestad L, Vagelos R, Bellin D, Ross H, Fowler MB. Cardiopulmonary exercise testing and prognosis in severe heart failure: 14 mL/kg/min revisited. *Am Heart J*. 2000;139(11):78–84.
6. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmonds LH, Wilson JR. Value of pico exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. *Circulation*. 1991;83(3):778–86.
7. Arena R, Myers J, Williams MA, Gulati M, Kligfield P, Balady CJ, et al. Assessment of functional capacity in clinical and research settings: A scientific statement from the American Heart Association committee on exercise, rehabilitation, and prevention of the council on clinical cardiology and the council on cardiovascular n. *Circulation*. 2007;116(3):329–43.
8. Master A, Oppenheimer E. A simple exercise tolerance test for circulatory efficiency with standard tables for normal individuals. Vol. 177, *Am J Med Sci*. 1929. p. 223–42.
9. Peterson PN, Magid DJ, Ross C, Ho PM, Rumsfeld JS, Lauer MS, Lyons EE, Smith SS MF. Association of Exercise Capacity on Treadmill With Future Cardiac Events in Patients Referred for Exercise Testing. 2014;168(2):174–9.
10. Kodama S, Saito K, Tanaka S, Maki M, Yachi Y, Asumi M, Sugawara A, Totsuka K, Shimano H, Ohashi Y, Yamada N SH. Cardiorespiratory Fitness as a Quantitative Predictor of All-Cause Mortality and Cardiovascular Events. *J Am Med Assoc*. 2009;301(19):2024–35.
11. ATS. Guidelines for the six-minute walk test. *Am J Respir Crit Care Med*. 2002;166(1):111–7.
12. da Costa CH, da Silva KM, Maiworm A, Raphael Y, Parnayba J, Da Cal M, et al. Can we use the 6-minute step test instead of the 6-minute walking test? An observational study. *Physiother (United Kingdom)* [Internet]. 2017;103(1):48–52. Available from: <http://dx.doi.org/10.1016/j.physio.2015.11.003>
13. Pessoa B V., Arcuri JF, Labadessa IG, Costa JNF, Sentanin AC, Di Lorenzo VAP. Validity of the six-minute step test of free cadence in patients with chronic obstructive pulmonary disease. *Brazilian J Phys Ther* [Internet]. 2014;18(3):228–36. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-35552014000300228&lng=en&nr m=iso&tng=em
14. Arcuri JF, Borghi-Silva A, Labadessa IG, Sentanin AC, Candolo C PDLV. Validity and reliability of the 6-minute step test in healthy individuals: A Cross-sectional study. *Clin J Sport Med*. 2016;26(1):69–75.
15. Ritt LEF, Stein R, Ribeiro DS, Ribeiro RS, Pilar I, Borges Q, et al. Low Concordance Between the Nyha Class and Cardiopulmonary Exercise Test Variables in Heart Failure Patients. *J Am Coll Cardiol* [Internet]. 2019;73(9):1828. Available from: [http://dx.doi.org/10.1016/S0735-1097\(19\)32434-9](http://dx.doi.org/10.1016/S0735-1097(19)32434-9)



This is an open-access article distributed under the terms of the Creative Commons Attribution License